APA (7th ed.) Citation

AM, M., GV, L., A, K., H, T., J, W., K, F., . . . MA, D. (2024). POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. Neuro-oncology advances, 6(1), vdae033. https://doi.org/10.1093/noajnl/vdae033

Chicago Style (17th ed.) Citation

AM, Menzies, et al. "POLARIS: A Phase 2 Trial of Encorafenib Plus Binimetinib Evaluating High-dose and Standard-dose Regimens in Patients with BRAF V600-mutant Melanoma with Brain Metastasis." Neuro-oncology Advances 6, no. 1 (2024): vdae033. https://doi.org/10.1093/noajnl/vdae033.

MLA (9th ed.) Citation

AM, Menzies, et al. "POLARIS: A Phase 2 Trial of Encorafenib Plus Binimetinib Evaluating High-dose and Standard-dose Regimens in Patients with BRAF V600-mutant Melanoma with Brain Metastasis." Neuro-oncology Advances, vol. 6, no. 1, 2024, p. vdae033, https://doi.org/10.1093/noajnl/vdae033.